Paclitaxel

製品コードS1150 別名:NSC 125973

Paclitaxel化学構造

分子量(MW):853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 44820.00

カスタマーフィードバック(4)

  • Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

    Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

  • Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

    Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

製品安全説明書

Microtubule Associated阻害剤の選択性比較

生物活性

製品説明 Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
ターゲット
Microtubule (human endothelial cells) [1]
0.1 pM
体外試験

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 NXzZVW9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPHe4RKSzVyPUCuNFAxOjh5IN88US=> NFTseGpUSU6JRWK=
LC-2-ad NF7wOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrSWI5CUUN3ME2wMlAxODNzNzFOwG0> M{f1PHNCVkeHUh?=
RL95-2 M1KxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfCcVhKSzVyPUCuNFAxPjZ6IN88US=> M1;QVnNCVkeHUh?=
MZ1-PC NEi4TWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrGclZZUUN3ME2wMlAxODd{OTFOwG0> NYHS[|NKW0GQR1XS
TE-8 NXm0O4dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;aTWM2OD1yLkCwNVE4KM7:TR?= MXzTRW5ITVJ?
SW954 NXPvU|NJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHOXJBmUUN3ME2wMlAxOTF7IN88US=> MnvnV2FPT0WU
TE-11 NGPDcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMECxNlMh|ryP MoHjV2FPT0WU
PSN1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfsV5kyUUN3ME2wMlAxOTNizszN MVXTRW5ITVJ?
MOLT-4 MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXNZlVKSzVyPUCuNFAyPDlizszN NWntdWx3W0GQR1XS
697 M{PDR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLtTnV3UUN3ME2wMlAxOTVizszN NEDvNo1USU6JRWK=
ETK-1 Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDWVnJRUUN3ME2wMlAxOTV{IN88US=> NHzONnFUSU6JRWK=
TE-10 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofkTWM2OD1yLkCwNVU1KM7:TR?= M2jQe3NCVkeHUh?=
HUTU-80 Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjQfVBKSzVyPUCuNFAyPjhizszN NGX1SmtUSU6JRWK=
NTERA-S-cl-D1 M1j4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvzTWM2OD1yLkCwNlA6KM7:TR?= MkPyV2FPT0WU
MFH-ino MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLzcotKSzVyPUCuNFAzPjhizszN M4e1cHNCVkeHUh?=
IA-LM MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TQb2lEPTB;MD6wNFI5KM7:TR?= NFu4cWZUSU6JRWK=
MC116 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPRWGFKSzVyPUCuNFAzQDlizszN M1q3U3NCVkeHUh?=
RKO MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvHbmMxUUN3ME2wMlAxOjl6IN88US=> M4j4O3NCVkeHUh?=
MRK-nu-1 M4eyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PC[GlEPTB;MD6wNFI6QSEQvF2= Ml\KV2FPT0WU
VA-ES-BJ NED0bo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G5TmlEPTB;MD6wNFMh|ryP MmfUV2FPT0WU
KALS-1 MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmL0TWM2OD1yLkCwN|A5KM7:TR?= M2DmXXNCVkeHUh?=
BB30-HNC NE\iZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXnSYFEUUN3ME2wMlAxOzF2IN88US=> MVHTRW5ITVJ?
ACN NIrrXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTaTWM2OD1yLkCwN|E3KM7:TR?= M2C4enNCVkeHUh?=
TE-9 NXjEUlFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMECzNlYh|ryP MnjzV2FPT0WU
SIG-M5 M3ixN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\ob4xKSzVyPUCuNFA{OjdizszN NVLuSG1pW0GQR1XS
no-10 NXXPO3BKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWWwRZZyUUN3ME2wMlAxOzZ{IN88US=> NV[2OJBEW0GQR1XS
EW-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPDeYZKSzVyPUCuNFA{PzFizszN NWHzVYFtW0GQR1XS
SK-LMS-1 NWLFc3BbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HhdmlEPTB;MD6wNFQxOSEQvF2= MoriV2FPT0WU
GT3TKB MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;mTWM2OD1yLkCwOFM1KM7:TR?= MkLnV2FPT0WU
ES4 MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwMEC0OFkh|ryP NULFV416W0GQR1XS
IMR-5 NUXrNJJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwMEC0OUDPxE1? M33FXHNCVkeHUh?=
NCI-H1648 M{[3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMEC0Olkh|ryP NFvvWlVUSU6JRWK=
MV-4-11 M1LEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWi3cHB5UUN3ME2wMlAxPDd3IN88US=> Mlj5V2FPT0WU
SK-UT-1 M335fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHpTWM2OD1yLkCwOFgh|ryP MmTsV2FPT0WU
NB13 M1;ENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{K1SGlEPTB;MD6wNFQ6OSEQvF2= NUXS[VAzW0GQR1XS
DJM-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDFfnQxUUN3ME2wMlAxPTNizszN M1jCeHNCVkeHUh?=
ES8 NGXsV3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMEC1N|gh|ryP M4fu[XNCVkeHUh?=
TE-6 M2q5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfZd3RKSzVyPUCuNFA2PyEQvF2= NFzY[FFUSU6JRWK=
KS-1 NFXtWJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF6wcmxKSzVyPUCuNFA2QDJizszN NHzMb25USU6JRWK=
TE-1 NGjNNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITnSYRKSzVyPUCuNFA3ODZizszN NU\mVpFDW0GQR1XS
ATN-1 NVf3PZE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jEWWlEPTB;MD6wNFYxQSEQvF2= M1\xXnNCVkeHUh?=
A4-Fuk MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\RdVFZUUN3ME2wMlAxPjFzIN88US=> NGHrWnFUSU6JRWK=
ALL-PO NWXQcYx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vX[mlEPTB;MD6wNFY{KM7:TR?= NEW2RWFUSU6JRWK=
BE-13 MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTGXVlrUUN3ME2wMlAxPjN4IN88US=> NV;HSmhvW0GQR1XS
KM12 MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3RUHFKSzVyPUCuNFA3OzdizszN MVzTRW5ITVJ?
NOS-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\5TWM2OD1yLkCwOlUh|ryP NFTTUHdUSU6JRWK=
SW962 NFPzSo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDKe2VKSzVyPUCuNFA3PjJizszN M2GzXXNCVkeHUh?=
OCUB-M NUXRVWtpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HNV2lEPTB;MD6wNFY3OiEQvF2= Mk\XV2FPT0WU
NCI-H510A M2Xvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnrV3Q5UUN3ME2wMlAxPjZ3IN88US=> MlXqV2FPT0WU
EW-16 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjSZWFOUUN3ME2wMlAxPjl2IN88US=> MkTWV2FPT0WU
KGN MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3BOYdKSzVyPUCuNFA4OTJizszN MWLTRW5ITVJ?
LS-411N NE\POopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMEC3NVch|ryP M3f4R3NCVkeHUh?=
Becker MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjzTWM2OD1yLkCwO|Ih|ryP MX;TRW5ITVJ?
HC-1 MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPxTWM2OD1yLkCwO|IyKM7:TR?= NXP1TVB3W0GQR1XS
CESS NIHYR5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMEC3N|ch|ryP MmXRV2FPT0WU
KURAMOCHI Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrndYVoUUN3ME2wMlAxPzR6IN88US=> MkfnV2FPT0WU
TGBC24TKB MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPVXGxSUUN3ME2wMlAxPzV{IN88US=> NUPNcGlzW0GQR1XS
SW982 NVrOToJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfKV5RpUUN3ME2wMlAxPzZ4IN88US=> MYTTRW5ITVJ?
HCE-4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLzTWM2OD1yLkCwO|Y4KM7:TR?= NXzUNJlFW0GQR1XS
LOUCY M37vWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nYRWlEPTB;MD6wNFc4PSEQvF2= NEnzTYxUSU6JRWK=
8-MG-BA MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vWemlEPTB;MD6wNFc6PiEQvF2= NIjpWmhUSU6JRWK=
HT-144 M13SOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfNTWM2OD1yLkCwPEDPxE1? MWXTRW5ITVJ?
LXF-289 NE\pNoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorYTWM2OD1yLkCwPFE5KM7:TR?= MnjVV2FPT0WU
RS4-11 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITPSIFKSzVyPUCuNFA5OzZizszN M1LrTHNCVkeHUh?=
DEL NVf2To1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITkVoVKSzVyPUCuNFA5PDVizszN NH35W2dUSU6JRWK=
OCI-AML2 MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwMEC4OVIh|ryP NHftcXZUSU6JRWK=
CCRF-CEM M4PJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMEC4O|Eh|ryP M3fQcXNCVkeHUh?=
A388 M1LoUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPhTWM2OD1yLkCwPFc1KM7:TR?= M2\hTnNCVkeHUh?=
KNS-42 NF32cJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{L1cmlEPTB;MD6wNFg6OSEQvF2= NUHob5NoW0GQR1XS
OVCAR-4 MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHi1VVlKSzVyPUCuNFA6ODRizszN NVe2cnFZW0GQR1XS
NCI-H1355 NVPIdYwzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO4Sod6UUN3ME2wMlAxQTF2IN88US=> NYDBd29YW0GQR1XS
BL-70 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrxUVdOUUN3ME2wMlAxQTNizszN MmrvV2FPT0WU
BL-41 NWflOHh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXoVHR7UUN3ME2wMlAxQTN2IN88US=> M1TDOXNCVkeHUh?=
A101D M1\JWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMEC5OkDPxE1? Ml;ZV2FPT0WU
HL-60 M1;2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMEC5OlYh|ryP MU\TRW5ITVJ?
COR-L279 NUPXd2xpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\Od2lEPTB;MD6wNFk6QSEQvF2= M4DnfnNCVkeHUh?=
NCI-SNU-16 M13wdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PYZWlEPTB;MD6wNVAxQCEQvF2= Mlv2V2FPT0WU
Calu-6 NEm5SmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEe1XWZKSzVyPUCuNFExOTJizszN M3T6VnNCVkeHUh?=
SR MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi5V3lKSzVyPUCuNFExOjZizszN MVPTRW5ITVJ?
QIMR-WIL MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorUTWM2OD1yLkCxNFM{KM7:TR?= MVrTRW5ITVJ?
LB647-SCLC NWXrW|lsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:4bWg3UUN3ME2wMlAyODVzIN88US=> NX3Ob5FqW0GQR1XS
RPMI-8226 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[1PXBKSzVyPUCuNFEyODJizszN M3LFWXNCVkeHUh?=
SK-PN-DW NV3BOIxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMEGxNVIh|ryP M4jjNHNCVkeHUh?=
SF268 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXXZnJKSzVyPUCuNFEyPTFizszN NUDiUnFIW0GQR1XS
HD-MY-Z M1WyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDKUGpKSzVyPUCuNFEyPjNizszN Mmr5V2FPT0WU
DOHH-2 M1GyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMEGyNFMh|ryP NEPpNpFUSU6JRWK=
SCC-3 Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnTTWM2OD1yLkCxNlA1KM7:TR?= MkXCV2FPT0WU
ST486 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMEGyNFQh|ryP Mkf3V2FPT0WU
NALM-6 M2XBW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\wOVE3UUN3ME2wMlAyOjF2IN88US=> MoXIV2FPT0WU
NCI-H1436 NXfMTYMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwMEGyN|Eh|ryP NF;MVphUSU6JRWK=
KE-37 NXrlcXZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXu[JlKSzVyPUCuNFEzOzRizszN MVrTRW5ITVJ?
RPMI-8402 MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULmSGh7UUN3ME2wMlAyOjV4IN88US=> NXzQdFl2W0GQR1XS
RXF393 MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\2RXNKSzVyPUCuNFEzPTdizszN MXzTRW5ITVJ?
KARPAS-45 NEjMNGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;oUWlEPTB;MD6wNVI4KM7:TR?= Ml7XV2FPT0WU
HOP-62 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETtVIxKSzVyPUCuNFEzPzZizszN NFfpVppUSU6JRWK=
ES1 NVzBeGtZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTPVmFKUUN3ME2wMlAyOjh6IN88US=> M1;OXXNCVkeHUh?=
L-363 M4jzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMEGzOVEh|ryP MnzuV2FPT0WU
GI-1 NEPaemJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrYeot1UUN3ME2wMlAyOzd|IN88US=> MWLTRW5ITVJ?
CTV-1 M{fIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPGTWM2OD1yLkCxOFc5KM7:TR?= NEfaToFUSU6JRWK=
TE-5 M{\0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMEG0PVYh|ryP NYTtXWxPW0GQR1XS
SNU-C2B MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;w[JlKSzVyPUCuNFE1QTZizszN M1jhc3NCVkeHUh?=
K-562 NYnVXXg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P5R2lEPTB;MD6wNVUyPiEQvF2= MW\TRW5ITVJ?
SNB75 MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke4TWM2OD1yLkCxOVQh|ryP NVnienlDW0GQR1XS
MOLT-13 NFPrVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HlbmlEPTB;MD6wNVY{PyEQvF2= MorrV2FPT0WU
LS-123 MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Htc2lEPTB;MD6wNVY3PCEQvF2= NXTFXnpUW0GQR1XS
NCI-SNU-5 NHf1cZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXtS|RKSzVyPUCuNFE4ODFizszN M2nsVXNCVkeHUh?=
Daudi M2H2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXwWItKSzVyPUCuNFE4ODhizszN MWrTRW5ITVJ?
A253 NYfQN2VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;ETWM2OD1yLkCxO|M5KM7:TR?= NX;FTHQ6W0GQR1XS
TGBC1TKB MkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3EOFBKSzVyPUCuNFE4PTJizszN MX\TRW5ITVJ?
SJSA-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwMEG3Olch|ryP M2fzN3NCVkeHUh?=
NCCIT NHm0ZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XVfmlEPTB;MD6wNVc3QSEQvF2= NWS1[ZN[W0GQR1XS
NCI-H69 NF\N[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPNTWM2OD1yLkCxO|c5KM7:TR?= NUG3[lk6W0GQR1XS
SH-4 M2nic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnS0TWM2OD1yLkCxPFk2KM7:TR?= NIL4NVBUSU6JRWK=
HCC1187 MoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jLcWlEPTB;MD6wNVkzPCEQvF2= NIrCN5NUSU6JRWK=
HCC1599 MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXyxV2xyUUN3ME2wMlAzODJizszN MXfTRW5ITVJ?
ONS-76 M3\Ud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\xTWM2OD1yLkCyNFM3KM7:TR?= M4LhWnNCVkeHUh?=
KU812 MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37DNmlEPTB;MD6wNlA{QSEQvF2= Ml\0V2FPT0WU
ML-2 M3fQN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvt[HpKSzVyPUCuNFIxPDdizszN M3HMdXNCVkeHUh?=
HCE-T M2nyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDIbXZKSzVyPUCuNFIxQTJizszN NELibZFUSU6JRWK=
NCI-H446 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTMZlhKSzVyPUCuNFIyOTJizszN MmXYV2FPT0WU
RPMI-6666 M2HoTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PH[mlEPTB;MD6wNlE1QSEQvF2= MoTlV2FPT0WU
MOLT-16 NFPEb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwMEKxOVMh|ryP MXTTRW5ITVJ?
JiyoyeP-2003 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH3O41[UUN3ME2wMlAzOTd4IN88US=> M17Ib3NCVkeHUh?=
MHH-PREB-1 NUe4Z2NDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMEKxPVEh|ryP NH\nfXFUSU6JRWK=
MC-CAR MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jseGlEPTB;MD6wNlMzPiEQvF2= MXrTRW5ITVJ?
BC-3 M4LQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknrTWM2OD1yLkCyN|Q1KM7:TR?= NYTjW2h4W0GQR1XS
KINGS-1 M3nUdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPUdFhbUUN3ME2wMlAzOzV3IN88US=> MVHTRW5ITVJ?
PF-382 M{frcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvmR5NKSzVyPUCuNFI{PzhizszN NYHCNmZlW0GQR1XS
J-RT3-T3-5 Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f4V2lEPTB;MD6wNlM5OyEQvF2= NV3Ue4NYW0GQR1XS
SF539 NGDnNWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn33TWM2OD1yLkCyOFAyKM7:TR?= NUH3fHJwW0GQR1XS
LB831-BLC M3;M[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\3TWM2OD1yLkCyOFg2KM7:TR?= Mn3kV2FPT0WU
DMS-114 M3XhbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHsTWM2OD1yLkCyOVAzKM7:TR?= M13BOXNCVkeHUh?=
LB1047-RCC NYfvUG8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDISnlRUUN3ME2wMlAzPTFizszN NIrMSGFUSU6JRWK=
LB771-HNC NIWzfWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwMEK1N|Qh|ryP M1vtR3NCVkeHUh?=
BB65-RCC Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwMEK1N|Qh|ryP NGTFcWtUSU6JRWK=
BV-173 NWTCe4pPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrPXJFKSzVyPUCuNFI2PTRizszN NHrzVmlUSU6JRWK=
ARH-77 NIK0UZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHZTWM2OD1yLkCyOlAyKM7:TR?= M2npdHNCVkeHUh?=
IST-MEL1 NXPL[XNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwMEK2NlMh|ryP MYDTRW5ITVJ?
NB1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwMEK2PFch|ryP MXvTRW5ITVJ?
EoL-1-cell NHL2NmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonMTWM2OD1yLkCyOlg5KM7:TR?= MVjTRW5ITVJ?
KY821 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv1b3RWUUN3ME2wMlAzPjl5IN88US=> Mmn4V2FPT0WU
CMK M{n6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH6cmZsUUN3ME2wMlAzPzN2IN88US=> M3z2[3NCVkeHUh?=
NCI-H2126 NH\mR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXziVpVJUUN3ME2wMlAzPzZ6IN88US=> MW\TRW5ITVJ?
NCI-H526 NV\nSpV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMEK4PVEh|ryP MUfTRW5ITVJ?
COLO-684 NH7BVoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jQOWlEPTB;MD6wNlkxQCEQvF2= M3zwfXNCVkeHUh?=
NCI-H747 NFW3d2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMEK5N|Mh|ryP M4XUNHNCVkeHUh?=
JAR NFr4VW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfFR5JxUUN3ME2wMlAzQTR4IN88US=> MWfTRW5ITVJ?
MEG-01 NH3mendIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjtTWM2OD1yLkCyPVc5KM7:TR?= NVTxS253W0GQR1XS
MONO-MAC-6 M4DWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMEOwNlMh|ryP NFqy[41USU6JRWK=
IST-SL1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjpWJZKSzVyPUCuNFMxPDJizszN NFfWOXpUSU6JRWK=
CPC-N MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMEOwO|kh|ryP M3nqb3NCVkeHUh?=
NCI-H1963 NVrmRmZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMEOxN|Eh|ryP MWXTRW5ITVJ?
K052 M{jkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS0TWM2OD1yLkCzNlQ4KM7:TR?= NYDU[|ZjW0GQR1XS
KM-H2 M1vTdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIX3c2dKSzVyPUCuNFM{ODdizszN Ml;KV2FPT0WU
TE-12 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMEOzNFkh|ryP MX\TRW5ITVJ?
TK10 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\vTHdKSzVyPUCuNFM{PTZizszN MX7TRW5ITVJ?
NMC-G1 M2jFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPIeVd2UUN3ME2wMlA{PDV{IN88US=> NFLycHZUSU6JRWK=
no-11 MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrxeINCUUN3ME2wMlA{PDd6IN88US=> NX3lNndqW0GQR1XS
NCI-H524 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFKwPVlKSzVyPUCuNFM2OjlizszN M3HtVXNCVkeHUh?=
MHH-CALL-2 M1XwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1e4PWlEPTB;MD6wN|U3OiEQvF2= MmfZV2FPT0WU
GB-1 NYLwVpdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7jeY9KSzVyPUCuNFM3KM7:TR?= NX7ldoJjW0GQR1XS
OPM-2 NUDhUW9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjETZNoUUN3ME2wMlA{Pjd|IN88US=> NVSzXm1qW0GQR1XS
RH-1 MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVm0NJIzUUN3ME2wMlA{QDF7IN88US=> NEXzNmtUSU6JRWK=
NCI-H64 MojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfrXJRKSzVyPUCuNFM5PTdizszN NW[zd2w4W0GQR1XS
EVSA-T MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[3d2lEPTB;MD6wN|kzOyEQvF2= Ml;XV2FPT0WU
KARPAS-299 NHrNfVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XsV2lEPTB;MD6wN|k5KM7:TR?= NWrxRXdEW0GQR1XS
MZ7-mel M2jI[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLQTWM2OD1yLkC0NFQh|ryP NWLYb2lJW0GQR1XS
LB373-MEL-D NULGXY9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXVSIpIUUN3ME2wMlA1OTB3IN88US=> M{e4V3NCVkeHUh?=
HEL MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\L[2lEPTB;MD6wOFE1KM7:TR?= MlLKV2FPT0WU
SW872 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vqWGlEPTB;MD6wOFIyKM7:TR?= NUHWSXdtW0GQR1XS
DU-4475 NYDVeZZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDvTWM2OD1yLkC0NlQ1KM7:TR?= M{foV3NCVkeHUh?=
IST-SL2 M2PxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHiTWM2OD1yLkC0Nlc2KM7:TR?= MmHFV2FPT0WU
NCI-H82 MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMESzNFch|ryP NYTxS4N4W0GQR1XS
LC4-1 MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[0TWM2OD1yLkC0N|UyKM7:TR?= NUfuc5JHW0GQR1XS
HDLM-2 M{LzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLLTWM2OD1yLkC0N|kzKM7:TR?= MWfTRW5ITVJ?
MMAC-SF Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q0eGlEPTB;MD6wOFU{PCEQvF2= MWfTRW5ITVJ?
L-540 Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLnUWtKSzVyPUCuNFQ3OzlizszN MWrTRW5ITVJ?
MZ2-MEL MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{X4TmlEPTB;MD6wOFc1OiEQvF2= MWDTRW5ITVJ?
LU-134-A MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13DNmlEPTB;MD6wOFc4OyEQvF2= MlLMV2FPT0WU
UACC-257 NWTXSmZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfVc5hOUUN3ME2wMlA1QDR7IN88US=> MkDaV2FPT0WU
NCI-H1581 MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7jXJlKSzVyPUCuNFQ6PTNizszN MnrSV2FPT0WU
NB17 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j6W2lEPTB;MD6wOFk4QSEQvF2= MmHIV2FPT0WU
SBC-1 M2LrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMEWwOFIh|ryP M2LjPXNCVkeHUh?=
TALL-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3FTWM2OD1yLkC1NFQ2KM7:TR?= MoTDV2FPT0WU
NCI-H1304 M4[4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnrcWxKSzVyPUCuNFUzODhizszN NGDCdoJUSU6JRWK=
NEC8 NVThOGZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMEWyPFYh|ryP MV3TRW5ITVJ?
CAL-148 NFHRS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;MTVVKSzVyPUCuNFU1OzlizszN Mn3TV2FPT0WU
CGTH-W-1 NHn3eopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PpUWlEPTB;MD6wOVQ1QSEQvF2= MlXDV2FPT0WU
NCI-H889 Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\KTWM2OD1yLkC1OVkzKM7:TR?= NHHXXotUSU6JRWK=
GR-ST MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMEW2NlEh|ryP NUjLXXNuW0GQR1XS
KARPAS-422 M1yz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfwPZNCUUN3ME2wMlA2PjVizszN MUfTRW5ITVJ?
RPMI-8866 NWH4eXNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMEW3NVIh|ryP NFvDfm5USU6JRWK=
SCLC-21H NEHGTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf6TWM2OD1yLkC1PFg1KM7:TR?= NGfsNJdUSU6JRWK=
COR-L88 NIDSfI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPUcoVlUUN3ME2wMlA2QTJ5IN88US=> NEL4NVJUSU6JRWK=
LU-139 NFPFOodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljGTWM2OD1yLkC1PVg3KM7:TR?= NWewT2FrW0GQR1XS
SF126 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37JR2lEPTB;MD6wOlE{OyEQvF2= MWDTRW5ITVJ?
NCI-H1882 NVrDPIs2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwME[0NlQh|ryP MX3TRW5ITVJ?
EW-24 NELL[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfiTWM2OD1yLkC2OFg{KM7:TR?= M13wVXNCVkeHUh?=
CP67-MEL M3GzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\n[GlEPTB;MD6wOlgyKM7:TR?= NXjYOZZ2W0GQR1XS
DG-75 MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vyOmlEPTB;MD6wOlg6QSEQvF2= NWnpfm9qW0GQR1XS
LOXIMVI NWLjd|BmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jBVWlEPTB;MD6wO|AzQCEQvF2= NV31UWttW0GQR1XS
HH NVTaS2NmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTj[VNKSzVyPUCuNFcyPTdizszN MXzTRW5ITVJ?
K5 NH7tT|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LJdGlEPTB;MD6wO|IzPiEQvF2= M3fvZnNCVkeHUh?=
EC-GI-10 NHTKVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HiOmlEPTB;MD6wO|I2PyEQvF2= Mn3JV2FPT0WU
SK-N-DZ M3q0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT0VWhWUUN3ME2wMlA4OzB5IN88US=> M{jnVHNCVkeHUh?=
A3-KAW NInJPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfVeJlKSzVyPUCuNFc{PTFizszN MnnFV2FPT0WU
MLMA NFnKS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rGTWlEPTB;MD6wO|Q3PSEQvF2= NXjFOXVTW0GQR1XS
LB996-RCC NF;aWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwMEe3NFch|ryP NHrMR4ZUSU6JRWK=
OS-RC-2 MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\5fmRKSzVyPUCuNFc4PDhizszN M3LJeXNCVkeHUh?=
CTB-1 NX7ES2tNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHGb3loUUN3ME2wMlA4QDFizszN M3\CXXNCVkeHUh?=
IST-MES1 Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3n6cGlEPTB;MD6wO|kyOiEQvF2= M{\qOnNCVkeHUh?=
LS-1034 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwMEiwN|Uh|ryP MV3TRW5ITVJ?
HT MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwMEiwPFYh|ryP NETGPGNUSU6JRWK=
NCI-H2141 M4HkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjMTWM2OD1yLkC4NUDPxE1? M3PiOXNCVkeHUh?=
LB2518-MEL NX;YUo5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q4WWlEPTB;MD6wPFE1OSEQvF2= MUHTRW5ITVJ?
GI-ME-N MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfHTWM2OD1yLkC4OFUzKM7:TR?= M1PVXXNCVkeHUh?=
TGW NXHCbnRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[0S2lEPTB;MD6wPFYxPyEQvF2= M1TicHNCVkeHUh?=
SK-NEP-1 Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LHOGlEPTB;MD6wPFY1OSEQvF2= NYP4WVBlW0GQR1XS
NOMO-1 M1rYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HGN2lEPTB;MD6wPVI4PSEQvF2= M1nRRXNCVkeHUh?=
ES6 M4DKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIL3VIVKSzVyPUCuNFk2QDlizszN NGPVdo1USU6JRWK=
NCI-H209 NVPoO5RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3O5dWlEPTB;MD6wPVc5PiEQvF2= MXfTRW5ITVJ?
GAK NUP5cXVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnXXIRZUUN3ME2wMlExOTZizszN NFfodXBUSU6JRWK=
BC-1 M4Pxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMUCzOlEh|ryP NWP0OlBOW0GQR1XS
KLE NI\wSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjjTWM2OD1yLkGwOFQ{KM7:TR?= NU[4U4U1W0GQR1XS
EW-3 M{H3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXGTHZ7UUN3ME2wMlExQThizszN NEm3UIxUSU6JRWK=
NKM-1 NY\yZplxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fYV2lEPTB;MD6xNVEh|ryP NVTTPVZrW0GQR1XS
D-336MG M4HrNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjOTnR6UUN3ME2wMlEyOjR2IN88US=> MUHTRW5ITVJ?
NB69 M2\2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwMUGzNFEh|ryP NUXtb|huW0GQR1XS
D-263MG NXPteFUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDQUoJTUUN3ME2wMlEyPzF{IN88US=> NH\ET2xUSU6JRWK=
KP-N-YS MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f1OWlEPTB;MD6xNlI6OSEQvF2= MkC0V2FPT0WU
NCI-H1155 MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nEV2lEPTB;MD6xNlU2QCEQvF2= NG\kXItUSU6JRWK=
BOKU MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHp[3ZOUUN3ME2wMlEzPTd7IN88US=> MlfnV2FPT0WU
LAMA-84 NVm5d4dMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXOTWM2OD1yLkGyPVkh|ryP MYTTRW5ITVJ?
Raji MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMUOxNVch|ryP NY[4N4ZsW0GQR1XS
LU-65 M4T5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMUOzNFch|ryP NWDzUJRJW0GQR1XS
NCI-H187 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DjRmlEPTB;MD6xN|kzPCEQvF2= NHLOWWtUSU6JRWK=
GCIY NHPUPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\mTWM2OD1yLkG0PVAyKM7:TR?= NVz3OlU6W0GQR1XS
NCI-H2107 M2jieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\hSINKSzVyPUCuNVUxQCEQvF2= NXfhNotzW0GQR1XS
NCI-H1522 NIPHOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX30W2RwUUN3ME2wMlE2OjZ4IN88US=> M4nLfXNCVkeHUh?=
NB6 NVPmU|hmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fhd2lEPTB;MD6xOVYzOyEQvF2= MVzTRW5ITVJ?
EM-2 M2HSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMUW3NFYh|ryP M3u3b3NCVkeHUh?=
HCC2218 M3X6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMUW5PEDPxE1? MUjTRW5ITVJ?
NCI-H748 NGjsSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMU[zO|Yh|ryP NFrZXJBUSU6JRWK=
MS-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwMU[1N|ch|ryP NUfUUXpwW0GQR1XS
NB5 NIX2cm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMU[1PVch|ryP NF7WTFhUSU6JRWK=
OMC-1 M2W1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rU[WlEPTB;MD6xOlY5QCEQvF2= M1TJR3NCVkeHUh?=
NCI-H345 NGDLR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr0PJNKSzVyPUCuNVY6OjhizszN M3L1eHNCVkeHUh?=
L-428 NGnUb4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMU[5OFUh|ryP NHPHPFRUSU6JRWK=
SCH MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPKO2ZKSzVyPUCuNVg3QDVizszN MmHHV2FPT0WU
NCI-H1417 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LzbmlEPTB;MD6xPVIzPyEQvF2= M3LJNnNCVkeHUh?=
COLO-320-HSR MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3zTY5RUUN3ME2wMlE6PTN{IN88US=> NVvHTo1lW0GQR1XS
BT-474 NHTFbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMkC4PVIh|ryP MlW0V2FPT0WU
GDM-1 NIDzeJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnZOJNwUUN3ME2wMlIyQTdzIN88US=> MV7TRW5ITVJ?
NCI-H2196 NVTDe3R7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMkKyN|Uh|ryP M3LyUnNCVkeHUh?=
KP-N-RT-BM-1 NF3LTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMkKzOFkh|ryP NFTufJBUSU6JRWK=
KNS-81-FD MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYj1em1FUUN3ME2wMlIzQTV6IN88US=> M3jqXHNCVkeHUh?=
COLO-668 M4m5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvqNWlmUUN3ME2wMlI{Pjd3IN88US=> MV7TRW5ITVJ?
C2BBe1 M3f4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\ITWM2OD1yLkK2O|Q4KM7:TR?= NFPkVnpUSU6JRWK=
Ramos-2G6-4C10 Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETC[GpKSzVyPUCuNlY6PTRizszN NVO2XXhlW0GQR1XS
CAS-1 M{L5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmD2TWM2OD1yLkK3NFk3KM7:TR?= M{O1XnNCVkeHUh?=
GOTO MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L5SGlEPTB;MD6yO|g6PCEQvF2= NVraW|M{W0GQR1XS
LP-1 M{jBUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMkiwOVch|ryP NVzjXYtrW0GQR1XS
NCI-SNU-1 MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHflU5lKSzVyPUCuNlk1OjJizszN NWjBU3ZCW0GQR1XS
EB-3 NGDrepNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13Ue2lEPTB;MD6yPVk4QSEQvF2= NWXsVIZyW0GQR1XS
MHH-NB-11 MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\2TWM2OD1yLkOwOFAzKM7:TR?= NHi0c3hUSU6JRWK=
SK-N-FI Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPib|RHUUN3ME2wMlMyPjl{IN88US=> MX7TRW5ITVJ?
HCC2157 NW[4c5ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTNdYtKSzVyPUCuN|M6OTNizszN Mm\MV2FPT0WU
SIMA NGSwS2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXsTVFKSzVyPUCuN|Q2QDFizszN MYXTRW5ITVJ?
MDA-MB-134-VI NH3mV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX0TWM2OD1yLkO2PVI5KM7:TR?= NEPJOGZUSU6JRWK=
NCI-H1694 MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mni2TWM2OD1yLkO3JO69VQ>? M4r3UnNCVkeHUh?=
EHEB NXHp[3V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnzcGxKSzVyPUCuN|kxQDVizszN MYrTRW5ITVJ?
U-266 M1jBW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwM{m4OFYh|ryP M2nLN3NCVkeHUh?=
LC-1F NWHtUIZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rneWlEPTB;MD60N|c3PSEQvF2= M2rlUXNCVkeHUh?=
SHP-77 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\1TWM2OD1yLkS3PFU2KM7:TR?= M{S2R3NCVkeHUh?=
LS-513 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu4TWM2OD1yLkS5N|A4KM7:TR?= NEDFeZVUSU6JRWK=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

+ 展開
  • 細胞株: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • 濃度: 0.1-100 pM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (参考用のみ)
動物試験:

[4]

+ 展開
  • 動物モデル: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • 製剤: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • 投薬量: 20 mg/kg
  • 投与方法: Administered via i.v.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
体内 左から右までの手順で、溶剤を製品に加えることです:
5% DMSO+5% Tween 80+ddH2O
2.5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管
別名 NSC 125973

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT03047265 Active, not recruiting Nasopharyngeal Carcinoma Sun Yat-sen University February 4, 2017 Phase 2
NCT02779855 Not yet recruiting Breast Cancer|Ductal Carcinoma|Invasive Breast Carcinoma|Invasive Ductal Breast Carcinoma H. Lee Moffitt Cancer Center and Research Institute|Amgen April 30, 2017 Phase 1|Phase 2
NCT00001426 Completed Ovarian Neoplasm National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 3, 1995 Phase 2
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1
NCT01051934 Completed Non-Small Cell Lung Cancer|Adenocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 29, 2009 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • 回答:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • 問題2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • 回答:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated信号経路図

相関Microtubule Associated製品

Tags: Paclitaxelを買う | Paclitaxel ic50 | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel化学構造 | Paclitaxel分子量 | Paclitaxel代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID